Your browser doesn't support javascript.
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Imran, Mohd; Kumar Arora, Mandeep; Asdaq, Syed Mohammed Basheeruddin; Khan, Shah Alam; Alaqel, Saleh I; Alshammari, Mohammed Kanan; Alshehri, Mohammed M; Alshrari, Ahmed Subeh; Mateq Ali, Alreshidi; Al-Shammeri, Ahmed Muteb; Alhazmi, Bushra Dhuhayyan; Harshan, Aishah Ali; Alam, Md Tauquir.
  • Imran M; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
  • Kumar Arora M; School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.
  • Asdaq SMB; Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
  • Khan SA; College of Pharmacy, National University of Science and Technology, Muscat 130, Oman.
  • Alaqel SI; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
  • Alshammari MK; Department of Pharmaceutical Care, Rafha Central Hospital, North Zone, Rafha 91911, Saudi Arabia.
  • Alshehri MM; Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh 11426, Saudi Arabia.
  • Alshrari AS; Medical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border University, Arar 91431, Saudi Arabia.
  • Mateq Ali A; Department of Medical Laboratory Sciences, Sulaiman ALrajhi University, Albukairah 51941, Saudi Arabia.
  • Al-Shammeri AM; Pharmaceutical Affairs, Dammam Health Network, Eastern Health Cluster, Dammam 31146, Saudi Arabia.
  • Alhazmi BD; Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
  • Harshan AA; Department of Pharmaceutical Care, Northern Area Armed Forces Hospital, King Khalid Military City Hospital, Hafr Al-Batin 31991, Saudi Arabia.
  • Alam MT; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
  • Abida; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
Molecules ; 26(19)2021 Sep 24.
Article in English | MEDLINE | ID: covidwho-1438674
ABSTRACT
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Cytidine / Drug Discovery / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxylamines Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Molecules26195795

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Cytidine / Drug Discovery / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxylamines Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Molecules26195795